原型帕纳克萨迪醇消除了帕金森病小鼠模型中的行为障碍和线粒体功能障碍
Jindong Zhao1,2, Ji Wang1,3, Kunying Zhao1,2
1School of Pharmaceutical Science & Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, 650500, People's Republic of China.
Neurochemical research
|March 29, 2024
概括
原型巴拿克萨迪醇 (PPDs),是人参酸的代谢物,在治疗帕金森病 (PD) 中具有潜力. 研究表明,R-PPD和S-PPD可以缓解PD模型中的行为缺陷,并保护PD模型免受神经退行.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 帕金森病 (PD) 是一种流行的神经退行性疾病,缺乏有效的治愈疗法.
- 黑色物质的紧性神经元 (SNc) 中的多巴胺能神经元退化是PD的标志.
- 来自人参酸的原型巴拿克沙醇 (PPD) 正在研究其神经保护潜力.
研究的目的:
- 研究R-PPD和S-PPD对PD小鼠模型中的行为缺陷和多巴胺基神经元损伤的治疗效果.
- 确定PPD是否可以减轻与PD相关的神经退行和线粒体功能障碍.
主要方法:
- MPTP诱导的帕金森病小鼠模型.
- 使用R-PPD和S-PPD (20 mg/kg,口腔食).
- 行为评估,多巴胺基神经元存活分析,线粒体功能测定和与亡相关的蛋白质 (Cyt C,Bax,caspase-3,BCL-2) 的西部斑点分析.
主要成果:
- 在PD模型小鼠中,R-PPD和S-PPD治疗显著缓解了MPTP诱导的行为缺陷.
- 保护PPD免受MPP+诱导的神经元损伤和线粒体功能障碍.
- 用R-PPD和S-PPD治疗减少了Cyt C,Bax,caspase-3和Bcl-2的异常表达,这表明抑制了亡.
结论:
- 在帕金森病小鼠模型中,R-PPD和S-PPD显示出显著的神经保护作用.
- 这些发现表明,PPD作为改善帕金森病的潜在治疗剂具有前途.
- 对PPD的进一步研究可能会导致PD的新型治疗方法.
相关概念视频
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
01:15Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541